Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 73.95 CNY -3.08% Market Closed
Market Cap: 93.6B CNY
Have any thoughts about
Beijing Wantai Biological Pharmacy Enterprise Co Ltd?
Write Note

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Inventory
ÂĄ905.5m
CAGR 3-Years
31%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Inventory
ÂĄ3B
CAGR 3-Years
72%
CAGR 5-Years
92%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Inventory
ÂĄ690.4m
CAGR 3-Years
-14%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Inventory
ÂĄ341.8m
CAGR 3-Years
77%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Inventory
ÂĄ15.7B
CAGR 3-Years
33%
CAGR 5-Years
43%
CAGR 10-Years
57%
Imeik Technology Development Co Ltd
SZSE:300896
Inventory
ÂĄ49.8m
CAGR 3-Years
23%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
93.8B CNY
Industry
Biotechnology

In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.

Intrinsic Value
62.75 CNY
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Inventory?
Inventory
905.5m CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Inventory amounts to 905.5m CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Inventory growth rate?
Inventory CAGR 5Y
33%

Over the last year, the Inventory growth was 4%. The average annual Inventory growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 31% over the past three years , 33% over the past five years .

Back to Top